One treatment a year.
Life changing.
Developing long lasting retinal treatments that are truly transformational for patients with sight-threatening diseases.
Significant unmet needs remain for retinal patients
The overall prevalence of retinal disease continues to be a significant public health challenge. Millions of patients suffering these diseases can experience impaired vision or total loss of sight.
Current treatments typically only address one mechanism of retinal disease and may contribute to a suboptimal or non-response. There is a significant patient population that is unresponsive or becomes refractory to current treatments.
Current retinal treatments across indications require frequent intravitreal injections which places significant demands on patients, clinicians, and healthcare systems. This demanding treatment regimen invariably leads to missed appointments, patient drop-out, and suboptimal treatment outcomes.
Oxular’s technology is devised to change the way retinal patients are treated
-
Potent compounds
that specifically address multiple physiological pathways of retinal diseases.
-
Long-lasting drug products
that safely provide up to 12 months of treatment effects from a single administration.
-
Tissue-specific delivery
through routine, safe, and accurate drug deployment to the specific tissues involved in retinal disease.
Oxular’s innovative treatment approaches are designed to address patients' unmet needs
Goal of one treatment per year. Dramatically reduce the unsustainable treatment burden on patients, clinicians, and healthcare systems.
Long-lasting
Goal of one treatment per year. Dramatically reduce the unsustainable treatment burden on patients, clinicians, and healthcare systems.
Provide sustained treatment for up to one year. Potential to translate into more consistent treatment effects, better compliance, and lower patient drop-out rates.
Better efficacy
Provide sustained treatment for up to one year. Potential to translate into more consistent treatment effects, better compliance, and lower patient drop-out rates.
Reduces treatment side effects associated with intra-ocular delivery of certain agents, carriers and excipients.
Better safety
Reduces treatment side effects associated with intra-ocular delivery of certain agents, carriers and excipients.
Targeted, atraumatic microcatherization that does not penetrate retinal tissue. Safely depots long lasting drug products to deliver drug to retinal tissues.
Better delivery
Targeted, atraumatic microcatherization that does not penetrate retinal tissue. Safely depots long lasting drug products to deliver drug to retinal tissues.
Our technology
Oxular’s technologies are designed to address the unmet needs of large patient populations.
Oxuspheres™ are designed to suit the unique ocular environments into which they are delivered, resulting in better drug distribution and longer-lasting treatment effects.
The Oxulumis™ technology is designed to enable minimally invasive, routine administration to the suprachoroidal, subretinal, and other small spaces in the eye.
Building lasting value
Oxular’s leadership is committed to developing treatments that are truly life-changing for patients suffering from sight-threatening diseases. The company is well positioned to drive its future growth as a clinical-stage retinal therapeutics company.
The pipeline
Oxular’s development pipeline includes treatments for prevalent retinal diseases and rare and orphan conditions, including delivery of gene therapy.
